Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data.

However, a decreased risk of development of several types of cancer in patients treated with these therapies was observed in one study, 14 while another investigation found a nonsignificant trend of elevated risk of nonbreast cancers. 4 Intramuscular IFNβ-1a (Avonex ® ; Biogen Idec, Weston, MA) is a first-line disease-modifying therapy administered weekly for treatment of relapsing forms of MS.

also in 5,406 other papers